MAINZ BIOMED N.V.

QUCY · Nasdaq · SIC 2834: Pharmaceutical Preparations
61
SEC Filings

Business Summary

PART I General Historically, we have developed and sold in-vitro diagnostic (IVD) tests for the early detection of cancer. In March 2025, we acquired a license from Liquid Bioscience, Inc. to access a portfolio of novel mRNA biomarkers and AI developed proprietary algorithm, for the non-invasive detection of pancreatic cancer with a blood test. We have an exclusive license to develop such a test using these biomarkers and algorithm with the unilateral option to acquire them. We are also developi...

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionQUCYdiscussed_in_filing Artificial Intelligence
topic_mentionQUCYdiscussed_in_filing Quantum Computing
topic_mentionQUCYdiscussed_in_filing Cybersecurity
topic_mentionQUCYdiscussed_in_filing Trusted Computing
topic_mentionQUCYdiscussed_in_filing Blockchain & Crypto
topic_mentionQUCYdiscussed_in_filing Supply Chain
topic_mentionQUCYdiscussed_in_filing Regulation
topic_mentionQUCYdiscussed_in_filing Healthcare & Bio
topic_mentionQUCYdiscussed_in_filing Platform & Ecosystem
topic_mentionQUCYdiscussed_in_filing Sovereign & Government
topic_mentionQUCYdiscussed_in_filing Artificial Intelligence
topic_mentionQUCYdiscussed_in_filing Quantum Computing
topic_mentionQUCYdiscussed_in_filing Cybersecurity
topic_mentionQUCYdiscussed_in_filing Trusted Computing
topic_mentionQUCYdiscussed_in_filing Blockchain & Crypto
topic_mentionQUCYdiscussed_in_filing Supply Chain
topic_mentionQUCYdiscussed_in_filing Regulation
topic_mentionQUCYdiscussed_in_filing Healthcare & Bio
topic_mentionQUCYdiscussed_in_filing Platform & Ecosystem
topic_mentionQUCYdiscussed_in_filing Sovereign & Government

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001213900-26-037676EDGAR45K words

Quarterly Reports (10-Q)

No 10-Q filings indexed.

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-250001213900-26-034103EDGAR1K words
2026-03-170001213900-26-028672EDGAR—
2026-03-110001213900-26-025940EDGAR—
2026-02-170001213900-26-016890EDGAR—
2026-02-100001213900-26-014378EDGAR—

61 total filings indexed. 55 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001874252
TickerQUCY
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedP7

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 703796d3e666ca799ab58ee52487242933babb92abcddc002f7d1c67259e275c
parent: 2d435d272ab6968ba4cf7c104edebdf8a3de59768b7bb1e83ecbba8b61aac306
content hash: 20f22111bafdf79a2f04caacff47a323c9ad8c959c86e466a433f23566a4c64d
signed: 2026-04-13T04:47:06.218Z
sources: 1 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf